• news.cision.com/
  • Let'em know AB/
  • Ilya Pharma extends global patent coverage for ILP100 for the treatment of diseases of skin and mucosa in humans and animals

Ilya Pharma extends global patent coverage for ILP100 for the treatment of diseases of skin and mucosa in humans and animals

Report this content

Low manufacturing costs, excellent temperature stability and high efficacy attracting increasing attention

Uppsala, May 23, 2022: Ilya Pharma (the Company), a clinical stage immunotherapy company today announced that the Indian Patent Office (IPO) has issued the Company Patent No 395551 titled “Methods for Wound Healing”. The patent covers the general use of a plasmid capable of expressing the protein CXCL12 in L. reuteri. The modified bacteria may be used for treatment of both mucosal and cutaneous wounds in humans and animals. These claims protect inventions which are central to the Company’s programs for treating human and animal wounds and follow the awards of related US patent and EU patents.

Ilya is currently developing a portfolio of three first-in-class immunotherapies for skin and mucosal diseases, including ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic ulcers and ILP100-Oral for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors.

CEO and Co-Founder Evelina Vågesjö comments: “We are delighted to have received this patent in India, being an important market, to add to our increasingly robust patent portfolio. Our approach is attracting increasing interest because of both the low cost of manufacture and excellent temperature stability. As stated previously, we believe that this patent further supports the recognition of the therapeutic utility of genetically modified bacteria in the “bugs for drugs” debate.”

Notes to editors. 

About Ilya Pharma - Ilya Pharma is a clinical stage biopharma company, developing novel drug candidates from its proprietary technology platform to clinical proof of concept in relevant patient groups with identified unmet medical needs.  The lead drug candidate ILP100 is also known as emilimogene sigulactibac as recommended by the WHO. www.ilyapharma.se

For more information, please contact:

Evelina Vågesjö, CEO Tel: +46 (0) 70 636 64 94 

Email: evelina.vagesjo@ilyapharma.se


RHApr - Richard Hayhurst  Tel: +44 (0) 7711 821527

Email: richard@rhapr.eu